Quadrant Capital Group’s Korro Bio KRRO Stock Holding History

Quadrant Capital Group’s Portfolio KRRO Stock Details KRRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-37	Closed	-$9K	–	2596
2021 Q4	$9K	Buy	+37	New	+$11.2K	﹤0.01%	1671

Other funds holding KRRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Quadrant Capital Group's KRRO Position: Q1 2022 in Review

Quadrant Capital Group sold out of Korro Bio (KRRO) in Q1 2022, closing a stake of 37 shares — an estimated $9K sold.

Quadrant Capital Group first reported a position in KRRO in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 85 funds tracked by Wall St. Rank hold KRRO as of Q1 2022.

Quadrant Capital Group reported no remaining Korro Bio position as of Q1 2022 after selling out during the quarter.
Quadrant Capital Group sold 37 Korro Bio shares in Q1 2022, an estimated $9K.
Quadrant Capital Group first reported a position in Korro Bio in Q4 2021 and held it in 1 quarter.
Quadrant Capital Group's Korro Bio position peaked at $9K in Q4 2021.
85 funds tracked by Wall St. Rank held Korro Bio as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.